Cardiometabolic Outcomes With Light Exposure During Sleep

NCT05317559 | Completed

• 1 other identifier: STU00094737
• Study Type: interventional
• Target: 20
• Locations: 0 countries
• Sites: N/A

Brief Summary

This study tested the hypothesis that acute exposure to light during nighttime sleep adversely affects cardiometabolic function.

Conditions

Light

Keywords

light; sleep; metabolism; sympathetic nervous system; insulin resistance

Outcome Measures

Primary Outcomes (4)

• Matsuda Index

  OGTT

  Day 2

• Matsuda Index

  OGTT

  Day 3

• HOMA-IR

  Fasting

  Day 2

• HOMA-IR

  Fasting

  Day 3

Secondary Outcomes (10)

• Sleep Stages

  Night 1

• Sleep Stages

  Night 2

• Sleep Stages

  Night 3

• Heart Rate

  Night 2

• Heart Rate

  Night 3

Other Outcomes (6)

• Melatonin

  Day 2

• Melatonin

  Day 3

• subjective sleepiness

  Day 2

Study Arms (2)

room light

EXPERIMENTAL

The room light condition (n=10) included one night of sleep in dim light (\< 3 lux) followed by one night of sleep with overhead room lighting (100 lux).

Behavioral: room light

dim light

NO INTERVENTION

The dim light condition (n=10) included two consecutive nights of sleep in dim light.

Interventions

room light BEHAVIORAL

The room light condition (n=10) included one night of sleep in dim light (\< 3 lux) followed by one night of sleep with overhead room lighting (100 lux). The dim light condition (n=10) included two consecutive nights of sleep in dim light.

room light

Eligibility Criteria

• Age: 18 Years - 40 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• healthy adults
• ages 18-40 years
• habitual sleep duration of 6.5-8.5 hours
• habitual sleep onset of 9:00 pm-1:00 am

You may not qualify if:

• any sleep disorder as assessed by history and screening questionnaires for obstructive sleep apnea (Berlin) and excessive daytime sleepiness (ESS \>12), and by PSG to exclude sleep apnea (apnea hypopnea index ≥ 15), periodic leg movements (movement arousal index ≥ 15), or REM sleep behavior disorder;
• history of a cognitive or neurological disorder;
• history of a major psychiatric disorder, including but not limited to mood/anxiety, eating, and alcohol/substance abuse disorders;
• depressed mood (Beck Depression Inventory II score ≥ 20);
• diabetes or other endocrine disorders;
• any gastrointestinal disease requiring dietary adjustment;
• blindness or significant vision loss;
• any unstable or serious medical conditions;
• current or recent (within the past month) of psychoactive, hypnotic, stimulant or analgesic medications;
• shift work or other types of self-imposed irregular sleep schedules;
• obesity (body mass index \> 30 kg/m2);
• history of habitual smoking (6 or more cigarettes per week) or drinking (7 or more alcoholic beverages per week) or caffeine consumption greater than 300 mg per day;
• current use of light therapy;
• use of any other legal or illicit substance that may affect sleep and/or appetite;
• allergy to heparin.

Sponsors & Collaborators

• Northwestern University: lead

MeSH Terms

Conditions

Insulin Resistance

Condition Hierarchy (Ancestors)

Hyperinsulinism; Glucose Metabolism Disorders; Metabolic Diseases; Nutritional and Metabolic Diseases

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: December 9, 2021
• First Posted: April 8, 2022
• Study Start: February 1, 2014
• Primary Completion: January 1, 2018
• Study Completion: July 1, 2018
• Last Updated: April 8, 2022

Record last verified: 2022-03

Data Sharing

• IPD Sharing: Will share